Company / Gross Profit
Bristol Myers Squibb Gross Profit History
FY2016-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$30.7B
FY2020
5-year range
-
FY2016-FY2020
Trend
+91.0%
vs FY2019
Sector context
#2 of 29
Health Care
What the data says
Among 29 Health Care companies, Bristol Myers Squibb is in the top 7% for gross profit. Improved from $14.7B to $30.7B over the past 2 years.
Based on SEC 10-K filings.
$30.7B in FY2020 with a 3-year CAGR of +27.9%. Ranks 2nd among 29 companies in Health Care.
Improved from $14.7B to $30.7B over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +27.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 29This company $30.7B Sector average $3.5B
▼
+788.1% above sector average
Key checks
Key Insights
- 3-year CAGR of +27.9%, indicating consistent growth.
- In FY2020, gross profit increased 91.0% year-over-year.
- Ranks #2 out of 29 companies in the Health Care sector.
- Lowest gross profit in the period was in FY2016.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $30.7B | +91.0% |
| FY2019 | $16.1B | +9.6% |
| FY2018 | $14.7B | +0.0% |
| FY2017 | $14.7B | +16.1% |
| FY2016 | $12.7B | +5.9% |
As of FY2020 · SEC 10-K · Updated Jun 30, 2026